Novel methods and tracers for breast cancer imaging

Seminars in Nuclear Medicine

Volumn 43, Issue 4, 2013, Pages 324-329

  Linden, Hannah M ^a   Dehdashti, Farrokh ^b  

^a Seattle Cancer Care Alliance   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABY 002 GA 68; AROMATASE INHIBITOR; CHOLINE C 11; CHOLINE F 18; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; KI 67 ANTIGEN; MEMBRANE LIPID; METHIONINE C 11; PROGESTERONE RECEPTOR; TAMOXIFEN; TRACER; TRASTUZUMAB IN 111; TRASTUZUMAB ZR 89; UNCLASSIFIED DRUG;

ADVANCED CANCER; AMINO ACID TRANSPORT; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER SCINTISCANNING; CELL PROLIFERATION; DRUG TARGETING; HORMONE RECEPTOR INTERACTION; HUMAN; IMAGE QUALITY; LIPOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR DENSITY; SCINTIMAMMOGRAPHY;

AMINO ACIDS; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; HUMANS; MEMBRANE LIPIDS; RADIOACTIVE TRACERS; RECEPTORS, STEROID;

EID: 84878376508     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2013.02.003     Document Type: Article

References (72)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 1 2012 10 29
2. W.L. McGuire Hormone receptors: Their role in predicting prognosis and response to endocrine therapy Semin Oncol 5 4 1978 428 433
3. Y. Zhan, N. Wang, and C. Liu A novel taspine derivative, HMQ1611, suppresses adhesion, migration and invasion of ZR-75-30 human breast cancer cells Breast Cancer 2012 Aug 9, [Epub ahead of print]
4. NCCN Guidelines. http://wwwnccnorg/professionals/physician-gls/pdf/ breastpdf
5. CAP Guidelines. http://wwwcaporg/apps/docs/laboratory-accreditation/ summary-of-recommendationspdf
6. E. Amir, N. Miller, and W. Geddie Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer J Clin Oncol 30 6 2012 587 592
7. J.F. Hilton, E. Amir, and S. Hopkins Acquisition of metastatic tissue from patients with bone metastases from breast cancer Breast Cancer Res Treat 129 3 2011 761 765
8. C. Simmons, N. Miller, and W. Geddie Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20 9 2009 1499 1504
9. J.A. Katzenellenbogen Designing steroid receptor-based radiotracers to image breast and prostate tumors J Nucl Med 36 suppl 6 1995 8S 13S
10. M.A. Mintun, M.J. Welch, and B.A. Siegel Breast cancer: PET imaging of estrogen receptors Radiology 169 1 1988 45 48
11. L.M. Peterson, D.A. Mankoff, and T. Lawton Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol J Nucl Med 49 3 2008 367 374
12. B.F. Kurland, L.M. Peterson, and J.H. Lee Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET J Nucl Med 52 10 2011 1541 1549
13. T. Tsuchida, H. Okazawa, and T. Mori In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET - Influence of menstrual cycle and endogenous estrogen level Nucl Med Biol 34 2 2007 205 210
14. T. Tsujikawa, Y. Yoshida, and T. Mori Uterine tumors: Pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET - Initial experience Radiology 248 2 2008 599 605
15. Y. Yoshida, Y. Kiyono, and T. Tsujikawa Additional value of 16alpha-[18F]fluoro-17beta-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET Eur J Nucl Med Mol Imaging 38 10 2011 1824 1831
16. M. van Kruchten, A.W. Glaudemans, and E.F. de Vries PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma J Nucl Med 53 2 2012 182 190
17. M. Paquette, R. Ouellet, and M. Archambault [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERalpha-knockdown breast tumors in mice Nucl Med Biol 39 1 2012 57 64
18. F. Dehdashti, J.E. Mortimer, and K. Trinkaus PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer Breast Cancer Res Treat 113 3 2009 509 517
19. P. Kumar, J. Mercer, and C. Doerkson Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients J Pharm Pharm Sci 10 2 2007 256s 265s
20. H.M. Linden, S.A. Stekhova, and J.M. Link Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer J Clin Oncol 24 18 2006 2793 2799
21. M. Gemignani, S. Patil, and E. Brogi Positron emission tomography (PET) and estrogen receptor (ER) ligand in patients with invasive breast cancer J Clin Oncol 28 15s 2010 617
22. J.E. Mortimer, F. Dehdashti, and B.A. Siegel Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy Clin Cancer Res 2 6 1996 933 939
23. J.E. Mortimer, F. Dehdashti, and B.A. Siegel Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer J Clin Oncol 19 11 2001 2797 2803
24. L.M. Peterson, B.F. Kurland, and H.M. Linden Early results of an NCI-sponsored phase II study of 18F-fluoroestradiol (FES) PET imaging of metastatic breast cancer J Nucl Med 53 2012 329
25. M.J. Ellis, F. Gao, and F. Dehdashti Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study J Am Med Assoc 302 7 2009 774 780
26. B.F. Kurland, V.K. Gadi, and J.M. Specht Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients Eur J Nucl Med Mol Imaging Res 2 1 2012 34
27. H.M. Linden, B.F. Kurland, and L.M. Peterson Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer Clin Cancer Res 17 14 2011 4799 4805
28. K.B. Horwitz, Y. Koseki, and W.L. McGuire Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen Endocrinology 103 5 1978 1742 1751
29. R. Natrajan, B. Weigelt, and A. Mackay An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers Breast Cancer Res Treat 121 3 2010 575 589
30. K.B. Horwitz, and W.L. McGuire Specific progesterone receptors in human breast cancer Steroids 25 4 1975 497 505
31. C. Lanari, C.A. Lamb, and V.T. Fabris The MPA mouse breast cancer model: Evidence for a role of progesterone receptors in breast cancer Endocr Relat Cancer 16 2 2009 333 350
32. R.J. Santen, A. Manni, and H. Harvey Endocrine treatment of breast cancer in women Endocr Rev 11 2 1990 221 265
33. V.J. Bardou, G. Arpino, and R.M. Elledge Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases J Clin Oncol 21 10 2003 1973 1979
34. C. Osborne, and D. Tripathy Aromatase inhibitors: Rationale and use in breast cancer Ann Rev Med 56 2005 103 116
35. J.H. Lee, H.B. Zhou, and C.S. Dence Development of [F-18]fluorine- substituted Tanaproget as a progesterone receptor imaging agent for positron emission tomography Bioconjug Chem 21 6 2010 1096 1104
36. F. Dehdashti, R. Laforest, and F. Gao Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16alpha,17alpha-[(R)- (1′-alpha-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione J Nucl Med 53 3 2012 363 370
37. A.M. Fowler, S.R. Chan, and T.L. Sharp Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer J Nucl Med 53 7 2012 1119 1126
38. M. Namer, C. Lalanne, and E.E. Baulieu Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer Cancer Res 40 5 1980 1750 1752
39. B.J. Furr, and V.C. Jordan The pharmacology and clinical uses of tamoxifen Pharmacol Ther 25 2 1984 127 205
40. S. Sjogren, M. Inganas, and A. Lindgren Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers J Clin Oncol 16 2 1998 462 469
41. C. Carlomagno, F. Perrone, and C. Gallo c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases J Clin Oncol 14 10 1996 2702 2708
42. A.D. Thor, D.A. Berry, and D.R. Budman erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer J Natl Cancer Inst 90 18 1998 1346 1360
43. K.I. Pritchard, L.E. Shepherd, and F.P. O'Malley HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 20 2006 2103 2111
44. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 16 2005 1659 1672
45. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 2005 1673 1684
46. S.J. Potts, J.S. Krueger, and N.D. Landis Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue Lab Invest 92 9 2012 1342 1357
47. R.J. Gonzalez, A.U. Buzdar, and W. Fraser Symmans Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin) Breast J 13 1 2007 72 75
48. N. Niikura, J. Liu, and N. Hayashi Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors J Clin Oncol 30 6 2012 593 599
49. J. Capala, and K. Bouchelouche Molecular imaging of HER2-positive breast cancer: A step toward an individualized 'image and treat' strategy Curr Opin Oncol 22 6 2010 559 566
50. 68Ga-labeled affibody molecules J Nucl Med 51 6 2010 892 897
51. 89Zr-trastuzumab for HER2/neu immunoPET imaging J Nucl Med 50 6 2009 974 981
52. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer Clin Pharmacol Ther 87 5 2010 586 592
53. R.L. Jones, J. Salter, and R. A'Hern The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer Breast Cancer Res Treat 116 1 2009 53 68
54. M.J. Ellis, V.J. Suman, and J. Hoog Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031 J Clin Oncol 29 17 2011 2342 2349
55. L. Kenny, R.C. Coombes, and D.M. Vigushin Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography Eur J Nucl Med Mol Imaging 34 9 2007 1339 1347
56. Q. Romero, P.O. Bendahl, and M. Klintman Ki67 proliferation in core biopsies versus surgical samples - A model for neo-adjuvant breast cancer studies BMC Cancer 11 2011 341
57. P.G. Febbo, M. Ladanyi, and K.D. Aldape NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology J Natl Compr Canc Netw 9 suppl 5 2011 S1 S32 [quiz S33]
58. M. Dowsett, T.O. Nielsen, and R. A'Hern Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer working group J Natl Cancer Inst 103 22 2011 1656 1664
59. J.R. Bading, and A.F. Shields Imaging of cell proliferation: Status and prospects J Nucl Med 49 suppl 2 2008 64S 80S
60. L.M. Kenny, A. Al-Nahhas, and E.O. Aboagye Novel PET biomarkers for breast cancer imaging Nucl Med Commun 32 5 2011 333 335
61. B.S. Pio, C.K. Park, and R. Pietras Usefulness of 3′-[F-18]fluoro- 3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy Mol Imaging Biol 8 1 2006 36 42
62. L.M. Kenny, D.M. Vigushin, and A. Al-Nahhas Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods Cancer Res 65 21 2005 10104 10112
63. K.R. Gray, K.B. Contractor, and L.M. Kenny Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies Phys Med Biol 55 3 2010 695 709
64. A. van Waarde, D.C. Cobben, and A.J. Suurmeijer Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model J Nucl Med 45 4 2004 695 700
65. K. Glunde, Z.M. Bhujwalla, and S.M. Ronen Choline metabolism in malignant transformation Nat Rev Cancer 11 12 2011 835 848
66. K.B. Contractor, L.M. Kenny, and J. Stebbing Biological basis of [(1)(1)C]choline-positron emission tomography in patients with breast cancer: Comparison with [(1)(8)F]fluorothymidine positron emission tomography Nucl Med Commun 32 11 2011 997 1004
67. U. Tateishi, T. Terauchi, and S. Akashi-Tanaka Comparative study of the value of dual tracer PET/CT in evaluating breast cancer Cancer Sci 103 9 2012 1701 1707
68. H. Miyazawa, T. Arai, and M. Iio PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: Relationship between radioactivity uptake and flow-cytometric parameters J Nucl Med 34 11 1993 1886 1891
69. S. Leskinen-Kallio, K. Nagren, and P. Lehikoinen Uptake of 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction Br J Cancer 64 6 1991 1121 1124
70. R. Huovinen, S. Leskinen-Kallio, and K. Nagren Carbon-11-methionine and PET in evaluation of treatment response of breast cancer Br J Cancer 67 4 1993 787 791
71. P. Lindholm, M. Lapela, and K. Nagren Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer Nucl Med Commun 30 1 2009 30 36
72. A. van Waarde, P.L. Jager, and K. Ishiwata Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation J Nucl Med 47 1 2006 150 154